medigraphic.com

2016, Number 3

<< Back Next >>

Cuba y Salud 2016; 11 (3)

Some new predictive factors of cardiovascular risk

Borges ML, Monserrate ÁI, Barroso BR, Turro PA, de la Torre NE

Language: Spanish
References: 37
Page: 51-55
PDF size: 210.61 Kb.


ABSTRACT

Objective: to describe some risk predictive factors of cardiovascular diseases with atherosclerosis causes that are not frequently considered in the prediction of cardiovascular risk.
Development: the risk factors are those biological signs or acquired habits that are present with more frequency in the patients with a real disease. The atherosclerosis cardiovascular disease has a multiple causes and the classic or traditional factors are divided into two big groups: not modifier as age, sex and family antecedents, and modifier as dyslipidemias, tobacco smoking, diabetes, arterial hypertension, obesity and sedentary lifestyle. The concept of new predictive factors of cardiovascular risk, identified from the etiopathogenic investigation of atherosclerosis and supported in clinical, epidemiological and laboratory observations have been considered nowadays predictors of independent risk, among the most studied: homocysteine (HCy); fibrinogen; uric acid; C-reactive protein and infections.
Conclusions: the importance in the elevation of values in blood like homocysteine, fibrinogen, uric acid, C-reactive protein and the relationship with infection diseases in the development of atherosclerosis were analyzed. Several of these factors are now predictors of independent risk.


REFERENCES

  1. Vega J, Guimará M, Vega L. Riesgo cardiovascular, una herramienta útil para la prevención de las enfermedades cardiovasculares. Rev Cubana Med Gen Integr[Internet] .2011 enero-marzo. [citado 9 Ago. 2016]; 27 (1).Disponible en: http://scielo.sld.cu/ scielo.php?script=sci_issuetoc&pid=0864-212520110001&lng=es&nrm=iso

  2. González G, Hernández S, Pozo P, García D. Asociación entre tejido graso abdominal y riesgo de morbilidad: efectos positivos del ejercicio físico en la reducción de esta tendencia. Nutrición Hospitalaria. 2011 julio - agosto; 26 (4).

  3. Acosta C, Herrera G, Rivera E, Mullings R, Martínez R . Epidemiología de los factores de riesgo cardiovascular y riesgo cardiovascular global en personas de 40 a 79 años en atención primaria. CorSalud. 2015 Enero-Marzo; 7 (1).

  4. Hackam MD, Anand MD. Emerging Risk Factors for Atherosclerotic Vascular Disease. A Critical Review of the Evidence. JAMA [Internet] 2003 Ago. [citado 9 Ago. 2016];290(7): 932-940).Disponible en: http://jama.jamanetwork.com/article. aspx?articleid=197101

  5. Carbayo JA. Nuevos marcadores de riesgo cardiovascular. ¿Pueden influir en la clasificación del riesgo cardiovascular? Clínica e investigación en arterioesclerosis. [Internet] 2012 .Mar. [citado 9 Ago. 2016]; 24(2).Disponible en: http://www.elsevier.es/en-revista-clinica-e-investigacion-arteriosclerosis-15-articulo-nuevos-marcadores-riesgocardiovascular- pueden-S0214916811002920?redirectNew=true

  6. Ryan D, Rouge B, Stone N, Stone N, Lloyd-Jones D, Eckel R, Medina H. ¿Qué dicen las nuevas guías para el tratamiento del Colesterol? Las Nuevas Guías de AHA/ACC. [Internet] 2013 Nov. 12. http://www.intramed.net/contenidover.asp?contenidoID=82172

  7. Lorenzatti A, Guzman LA, Cuneo CA. Nuevos factores de riesgo cardiovascular. Rev Fed Arg Cardiol. 1999; 28 (539-544).

  8. Suárez I, Gómez JF, Ríos JJ, Hernández B, Vázquez JJ. La homocisteína. ¿El factor de riesgo cardiovascular del próximo milenio? Anales de Medicina Interna. [Internet] 2001 abril; 18 (4). Disponible en: http://scielo.isciii.es/pdf/ami/v18n4/revision.pdf

  9. Blanco F. Hiperhomocistemia asociada a múltiples enfermedades, desde la aterotrombósis al Alzheimer: ¿casualidad o casualidad? PDF. 2012 abril;97 Disponible en: https://encolombia.com/medicina/revistas-medicas/academedicina/vol97/ conexion-homocisteina/

  10. De Jager CA. Critical levels of brain atrophy associated with homocysteine and cognitive decline. Neurobiol Aging. [Internet] 2014 Sept; 35Suppl 2 (S35-9). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24927906

  11. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB. Executive summary: heart disease and stroke statistics. American Heart Association. Circulation [Internet] 2012 [citado 9 Ago. 2016]; 125 (22).Disponible en: http://www. ncbi.nlm.nih.gov/pubmed/22215894

  12. Lin CP, Chen YH, Leo HB, Lin SJ, Chen YL. Anti-inflammatory strategies for homocysteine-related cardiovascular disease. Front Biosci. [Internet] 2009; [citado 11 Ago. 2016] 1 (14). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19273314

  13. Postea O, Krotz F, Henger A, Keller C, Weiss N. Stereospecific and redoxsensitive increase in monocyte adhesion to endotelial cells by homocysteine. Arterioscler Thromb Vasc Biol. [Internet] 2006; [citado 11 Ago. 2016] 26. [aprox.. 5 p.].Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16373615

  14. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endotelial cells: implications for vascular disease. Circulation. [Internet] 2001; [citado 12 Ago. 2016]; 103 [aprox. 6 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/11390343

  15. Doron RD, Muñoz CM. Marcadores Cardiacos y Riesgo Cardiovascular. Revista Médica Clínica Las Condes. [Internet] 2015[citado 12 Ago. 2016]Mar;26(2). Disponible en: http://www.sciencedirect.com/science/journal/07168640/26/2

  16. Mohan IV, Jagroop IA, Mikhailidis DP, Stansby GP. Homocysteine activates platelets in vitro. Clin Appl Thromb Hemost. [Internet] 2008; 14(1) [aprox. 10 p.] Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18160593

  17. Prontera C, Martelli N, Evangelista V. Homocysteine modulates the CD40/CD40L system. J Am Coll Cardiol. 2007; 49 (2182- 90)

  18. Yeboah J, R.L. McClelland, T.S. Polonsky. Comparaison of Novel Risk Markers for Improvement of Cardiovascular Risk Assessment in Intermediate Risk Individuals. JAMA. 2012; 308.p. 788–795.

  19. Youssef G, Budoff j. Coronary Artery Calcium Scoring What is anwsered and what question remain?. 2012; .2 .p. 94–105.

  20. Kavousi M, Suzette E, Rutten J.H.. Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification Ann Intern Med. 2012; 156.p. 438–444.

  21. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2013; 62 (13]. p. 1131-43. OJO INTERNET

  22. Berger S, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for Cardiovascular Risk in Asymptomatic Patients. J Am Coll Cardiol [Internet]. 2010 Mar. [citado 9 Ago. 2016]; 55 (12) 1169-77. Disponible en: http://content.onlinejacc.org/cgi/ reprint/55/12/1169.pdf.

  23. Sojo J. El fibrinógeno como factor de riesgo cardiovascular. Health and Medicine.[Internet] 2013 Nov.. Disponible en: http:// es.slideshare.net/casosclinicos/el-fibringeno-como-factor-de-riesgo-cardiovascular-jess-sojo-dorado-servicio-de-medicinainterna- hospital-universitario-virgen-macarena-alumno-del-mster-de-investigacin-biomdica

  24. Tamayo IC. El fibrinógeno y su importancia clínica. [Internet] 2015 Ago. [citado Ene. 15 2016]. Disponible en: https://prezi. com/rlgm3zkcpd3m/anticoagulante-lupico.

  25. Centro de Información Cardiovascular del Texas Heart Institute. [Internet]. 2015 [citado Feb. 20 2016]. Disponible en: www. nlm.nih.gov/medlineplus/spanish/metabolicsyndrome.html

  26. Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S, Takahashi H. Relation of change in apolipoprotein B/apolipoprotein A–I ratio to coronary plaque regression after Pravastatin treatment in patients with coronary artery disease. Am J Cardiol. 2010; 105 (2) .p. 144-8.

  27. Ácido úrico: una molécula con acciones paradójicas en la insuficiencia cardiaca. Rev.Méd. Chile. 2011[citado Nov. 30 2012]. abril; 139( 4).

  28. Guía práctica clínica para el manejo de la gota. American College of Rheumatology; 2012.

  29. Bombelli M, Ronchi I, Volpe M, Facchetti R, Carugo S, Dell’oro R. Prognostic value of serum uric acid: New-onset in and outof- office hypertension and long term mortality.. J Hypertens. 2014; vol.32 (pp: 1237-1244.).

  30. Park JH, Jin YM, Hwang S, Cho DH, Kang DH, Jo I. Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: A mechanism for uric acidinduced cardiovascular disease development. Nitric Oxi. 2013; 32 .p. 36-42.

  31. Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J. High serum uric acid and increased risk of type 2 diabetes: A systemic review and meta-analysis of prospective cohort studies. 2013 ;( vol.8).

  32. Kaptoge S, Di Angelantonio E, Pennells L . Emerging Risk Factors Collaboration. N Engl J Med. 2012; 367 .p.1310-1320.

  33. La Proteína C-reactiva y una nueva técnica que ayuda a predecir el riesgo de enfermedades cardiovasculares. Centro Integral de Medicina de Alta Complejidad. 2014 octubre.

  34. Heres de la Caridad F, Peix A, Bacallao J, González O, Ravelo R, Soto J, Flores A. Proteína C reactiva y factores de riesgo clásicos en pacientes con enfermedad arterial coronaria estable. Rev. Cubana de Cardiología y Cirugía Cardiovascular. [Internet]. 2014 [citado Feb. 20 2016]; 20 (4). Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/547

  35. González E, Montero M A, Schmidt J. Proteína-C reactiva como marcador bioquímico de riesgo cardiovascular. SENPE. [Internet] 2013 [citado Abr.. 20 2015];28(6). Disponible en: http://dx.doi.org/10.3305%2Fnutr+hosp.v28in06.6807).

  36. De Jager CA. Critical levels of brain atrophy associated with homocysteine and cognitive decline. Neurobiol Aging. [Internet] 2014 [citado Abr. 20 2015];35 (2).Disponible en: www.ncbi.nlm.nih.gov/pubmed/24927906.

  37. Figueroa Z, García L, Gil M, Fernández Y. Anticuerpos IgG anti-Helicobacter pylori Y anti-Chlamydia pneumoniae en pacientes con cardiopatía isquémica aguda. [Internet] 2015 abril [citado Ago.. 20 2015].Disponible en: https://www.researchgate.net/ publication/275334011_




2020     |     www.medigraphic.com